EUVIMEDEUVIMED entdecken
Crossref

Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen

John M Wentworth iD, Anna B E Sing, Gaetano Naselli, Dexing Huang, Elizabeth Azidis-Yates, Batsho Mandlebe, James D Brown, Kelly McGorm, Candice Hall, Leanne Redl, Renee Kludas, Aniruddh Haldar und 12 weitere

Diabetes Care · 01.04.2025 · 48 (4) · 556-563

DOI: 10.2337/dc24-2443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 29.01.2025. Verfasst von John M Wentworth und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Autoantibodies, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Diabetes Australia Research Trust, Medical Research Future Fund, JDRF Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Type1Screen offers islet autoantibody testing to Australians with a family history of type 1 diabetes (T1D) with the dual aims of preventing diabetic ketoacidosis (DKA) and enabling use of disease-modifying therapy. We describe screening and monitoring outcomes 2 years after implementing in-home capillary blood spot sampling. RESEARCH DESIGN AND METHODS Data from 2,064 participants who registered between July 2022 and June 2024 were analyzed: 1,507 and 557 chose blood spot and venipuncture screening respectively. We compared baseline characteristics and outcomes for 1,243 participants (967 blood spot and 276 venipuncture) whose samples were tested by June 2024. RESULTS One blood spot and five venous participants reported unsuccessful sample collections. The median (quartile 1, quartile 3) age of blood spot registrants was lower (12.1 [7.1, 27.1] vs. 17.2 [9, 38.4] years; P < 0.0001), and a higher proportion lived in regional Australia (39% vs. 29%; P = 0.0037). Among 72 participants (5.9%) with a positive screening test, 5 screened by blood spot and 2 by venipuncture had no autoantibodies on confirmatory testing. Blood spot screening identified the expected 2.1% prevalence of multiple autoantibodies and a 2.5% prevalence of a single autoantibody compared with 1.5% and 4.1%, respectively, for venipuncture screening. Clinical diabetes developed in 12 participants. All had screened positive and none had DKA. CONCLUSIONS Type1Screen has national reach. In-home blood spot screening is feasible, particularly for younger participants living regionally, and identifies the expected prevalence of preclinical T1D. The lower cost, increased convenience, and greater reach of blood spot screening could help meet increasing demand for early T1D diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesDiabetes Mellitus, Type 1HumansFemaleAdultAustraliaMaleMiddle AgedYoung AdultAdolescentChildBlood Specimen CollectionMass Screening

Substanzen

Autoantibodies

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
  • Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
  • Population Health and Immunity Division, Walter and Eliza Hall Institute, Parkville, Victoria, Australia.
  • St Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.
  • Faculty of Health and Medical Sciences, Adelaide Medical School, and Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia.
  • Endocrinology and Diabetes Department, Women's and Children's Hospital, North Adelaide, South Australia, Australia.

ORCID-Profile: John M Wentworth

Förderung

  • Diabetes Australia Research Trust
  • Medical Research Future Fund
  • JDRF Australia

Zitieren

APA

Wentworth, J. M., Sing, A. B. E., Naselli, G., Huang, D., Azidis-Yates, E., Mandlebe, B., Brown, J. D., McGorm, K., Hall, C., Redl, L., Kludas, R., Haldar, A., Healy, F., Gilbert, A., Watson, K., Chiang, C., Couper, J. J., Huynh, T., Davis, E. A., …, & Colman, P. G. (2025). Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen. Diabetes Care, 48(4), 556-563. https://doi.org/10.2337/dc24-2443

Vancouver

Wentworth JM, Sing ABE, Naselli G, Huang D, Azidis-Yates E, Mandlebe B, et al. Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen. Diabetes Care. 2025;48(4):556-563. doi:10.2337/dc24-2443

BibTeX
@article{Wentworth2025,
  author = {Wentworth, John M and Sing, Anna B E and Naselli, Gaetano and Huang, Dexing and Azidis-Yates, Elizabeth and Mandlebe, Batsho and Brown, James D and McGorm, Kelly and Hall, Candice and Redl, Leanne and Kludas, Renee and Haldar, Aniruddh and Healy, Felicity and Gilbert, Abbey and Watson, Kelly and Chiang, Cherie and Couper, Jennifer J and Huynh, Tony and Davis, Elizabeth A and Craig, Maria E and Cameron, Fergus J and Kay, Thomas W and Harrison, Leonard C and Colman, Peter G},
  title = {Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen},
  journal = {Diabetes Care},
  year = {2025},
  volume = {48},
  number = {4},
  pages = {556--563},
  doi = {10.2337/dc24-2443}
}
Kostenlos starten →